p63 Antibodies

Target Information

Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter. Belongs to the p53 family. Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues. 2 human isoforms generated by alternative promoter usage or alternative splicing have been reported. Note: This description may include information from UniProtKB.

Alternate Names

AIS; amplified in squamous cell carcinoma; B(p51A); B(p51B); Chronic ulcerative stomatitis protein; CUSP; deltaN-alpha; DeltaNp63; deltaNp63 alpha; EEC3; Keratinocyte transcription factor KET; KET; LMS; NBP; OFC8; p40; p51; p51delNalpha; p53CP; P63; p63 iso2; P73H; P73L; RHS; SHFM4; TP53CP; TP53L; TP63; TP73L; Transformation-related protein 63; Tumor protein 63; tumor protein p53-competing protein; tumor protein p53-like; tumor protein p63; tumor protein p63 deltaN isoform delta; Tumor protein p73-like